News
Academy
Publications
All PublicationsE-Books
Media
Editorial PodcastsEditorial VideosPeer ExchangePractice AcademySponsored PodcastsSponsored Videos
More
Conferences
Conference CoverageConference Listing
Columns
All ColumnsA Closing ThoughtClinical Trial InsightsView from BrusselsView from Washington
Resources
AdvertiseBlogsEventsFront & CenterPartner PerspectivesWhite Papers
Webcasts

Subscribe

  • News
  • Academy
  • Publications
  • Media
  • Conferences
  • Columns
  • Resources
  • Webcasts
  • Subscribe
  • Clinical Operations & Strategy
    • Decentralized Clinical Trials
    • Trial Design
    • Investigative Sites
    • CRO/Sponsor
    • Risk-Based Monitoring
    • Protocol Design
    • Clinical Trial Supply Chain
    • Study Start-Up
    • Early Phase Development
  • DEI
    • Industry Initiatives
    • Diversity Action Plans
    • Recruitment
  • Data Management
    • Analytics
    • Electronic Data Capture
    • Real World Evidence
    • Metrics & Benchmarks
  • Patient Participation
    • Integrated Research
    • CRAACO
    • Enrollment
  • Regulatory
    • Institutional Review Board & Ethics Committee
    • FDA
    • EMA
  • Technology
    • Artificial Intelligence/Machine Learning
    • eClinical
    • mHealth
Spotlight -
Conference Coverage|
Peer Exchange|
DE&I|
Editorial Videos|
CNS Drug Development Resources
Advertisement

Sean Neal

Advertisement

Client Services Principal, Medidata Solutions

Articles by Sean Neal

CDASHandE2B-821936-1408533192123.png

Practical Thoughts on Common Standards: CDASH and E2B for Safety Reporting

BySean Neal
September 3rd 2013

Clinical research is complicated, and it?s not just the science. Take CDASH, CDISC and E2B for example. Aren?t acronyms awesome?

Advertisement

Latest Updated Articles

  • CDASHandE2B-821936-1408533192123.png
    Practical Thoughts on Common Standards: CDASH and E2B for Safety Reporting

    Published: September 3rd 2013 | Updated:



Advertisement
Advertisement

Trending on Applied Clinical Trials Online

1

How the FDA’s CNPV Program Is Reshaping Trial Operations and Accelerated Review Strategies

2

Voyxact Lands FDA Accelerated Approval Following Positive Results in Phase III VISIONARY Trial

3

ACT Brief: The Evolving CRA Role, New Immunotherapy Standard in Gastric Cancer, and Priority Review for Higher-Dose Wegovy

4

Novo Nordisk Submits Higher-Dose Wegovy Injectable for FDA Approval with Priority Voucher

5

2025 Veeva R&D and Quality Summit: Effectively Utilizing Clinical Reference Data

  • About
  • Advertise
  • Contact Us
  • Editorial Contacts
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

  • Applied Clinical Trials
  • BioPharm International
  • Cannabis Science and Technology
  • Chromatography Online
  • Nutritional Outlook
  • Pharmaceutical Commerce
  • Pharmaceutical Executive
  • Pharm Tech
  • Spectroscopy Online
  • Turbo Machinery Magazine
IS1
Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us